Inflammation, Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2022

Conditions
Atrial FibrillationAtrial Inflammation
Interventions
DIAGNOSTIC_TEST

Cardiac imaging tests

2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will

DIAGNOSTIC_TEST

Venous blood samle collection

Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.

Trial Locations (1)

540102

Cardio Med Medical Center, Târgu Mureş

Sponsors
All Listed Sponsors
collaborator

University of Targu Mures, Romania

OTHER

collaborator

University Hospital of Targu Mures, Romania

OTHER

lead

Cardio Med Medical Center

INDUSTRY

NCT03757741 - Inflammation, Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation | Biotech Hunter | Biotech Hunter